Clinical evaluation of a newly developed enzyme-linked immunosorbent assay for the determination of plasma tumor type M2-pyruvate kinase

GAO Xiang,LU Renquan,GUO Lin

DOI: https://doi.org/10.3969/j.issn.1673-8640.2010.07.014

IF: 1.865

2010-01-01

Laboratory Medicine

Abstract:Objective To evaluate the methodological performance and clinical applicability of a newly developed enzyme-linked immunosorbent assay(ELISA) for the determination of plasma tumor type M2-pyruvate kinase(TU M2-PK).Methods The bias,imprecision and recovery of the new TU M2-PK assay were determined,and 371 clinical samples were tested.Results The results of the TU M2-PK assay showed good accuracy(bias<5 U/mL) and precision [coefficient of variation(CV)<10%].Compared with gold standard pathologic diagnosis,the TU M2-PK levels of 371 clinical samples were analyzed.The sensitivity and specificity were 69.7%(106/152) and 86.8%(190/219),respectively.The accuracy was 80.0%(296/371).The TU M2-PK concentration in malignant tumor patients was significantly higher than that in benign tumor patients and healthy controls(P<0.01).Conclusions The ELISA for the determination of TU M2-PK performs well and has the value of clinical application.